scholarly journals Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

2015 ◽  
Vol 26 (8) ◽  
pp. 1715-1722 ◽  
Author(s):  
J. Tie ◽  
I. Kinde ◽  
Y. Wang ◽  
H.L. Wong ◽  
J. Roebert ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Therapeutic Response ◽  
Circulating Tumor Dna ◽  
Early Marker ◽  
Tumor Dna

Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer

2018 ◽  
Vol 17 (10) ◽  
pp. 2238-2247 ◽  
Author(s):  
Hung-Chih Hsu ◽  
Nina Lapke ◽  
Chuang-Wei Wang ◽  
Pei-Yi Lin ◽  
Jeng Fu You ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Genetic Variants ◽  
Therapeutic Response ◽  
Circulating Tumor Dna ◽  
Targeted Sequencing ◽  
Tumor Dna

Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 3533-3533 ◽  
Author(s):  
Allan Andresson Lima Pereira ◽  
Michael Lam ◽  
Preeti Kanikarla Marie ◽  
Kanwal Pratap Singh Raghav ◽  
Van Karlyle Morris ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Clinical Benefit ◽  
Circulating Tumor Dna ◽  
Early Marker ◽  
Tumor Dna

Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 713-713
Author(s):  
Jianfeng Zhou ◽  
Ning Jia ◽  
Zhao Sun ◽  
Xin Gao ◽  
Yuejuan Cheng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Progressive Disease ◽  
Therapeutic Response ◽  
Progression Free Survival ◽  
Circulating Tumor Dna ◽  
Carbohydrate Antigen ◽  
First Line Therapy ◽  
Candidate Mutation ◽  
Tumor Dna

713 Background: Early biomarkers of therapeutic responses could help optimize the treatment of metastatic colorectal cancer (mCRC). This prospective study was designed to explore the serial changes in plasma-circulating tumor DNA (ctDNA) as an early marker of therapeutic response to systemic treatment in mCRC. Methods: Twenty-six mCRC patients receiving standard first-line therapy once every two weeks were enrolled. Plasma ctDNA, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) were assessed serially before each of the first four cycles. Somatic mutations in plasma ctDNA were detected via next-generation sequencing using a panel of 50 cancer-related genes, and the mutation of maximal frequency in pretreatment ctDNA was selected as the candidate mutation for analysis. Radiologic responses were assessed after the fourth cycle. Results: Mutations in pretreatment ctDNA could be detected in 25 (96.2%) of the 26 initially enrolled patients. Among the 20 patients monitored serially, changes in ctDNA could differentiate patients with progressive disease two cycles (approximately four weeks) earlier than the changes in CEA and CA19-9 levels could, and changes in ctDNA levels as early as prior to cycle 2 predicted the radiologic responses after cycle 4. A log2 value of fold-change in ctDNA after cycle 1 (log2 (C1/C0)) > 0.044 predicted progressive disease, with a sensitivity and specificity of 100.0% (95%CI: 47.8-100.0%) and 86.7% (95%CI: 59.5-98.3%), respectively, and an accuracy of 90.0% (95%CI: 68.3-98.8%). Patients with log2 (C1/C0) > 0.044 showed worse progression-free survival than did those with log2 (C1/C0) ≤0.044 (median 2.0 versus 17.0 months; P = 0.092). Conclusions: Early changes in ctDNA that are detected via targeted sequencing could predict later radiologic responses in mCRC.

scholarly journals Small EVs-Associated DNA as Complementary Biomarker to Circulating Tumor DNA in Plasma of Metastatic Colorectal Cancer Patients

2021 ◽  
Vol 14 (2) ◽  
pp. 128
Author(s):  
Silvia Galbiati ◽  
Francesco Damin ◽  
Dario Brambilla ◽  
Lucia Ferraro ◽  
Nadia Soriani ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Digital Pcr ◽  
Extracellular Vesicle ◽  
Circulating Tumor Dna ◽  
Mutation Status ◽  
Promising Practice ◽  
Colorectal Cancer Patients ◽  
Tumor Dna

It is widely accepted that assessing circular tumor DNA (ctDNA) in the plasma of cancer patients is a promising practice to evaluate somatic mutations from solid tumors noninvasively. Recently, it was reported that isolation of extracellular vesicles improves the detection of mutant DNA from plasma in metastatic patients; however, no consensus on the presence of dsDNA in exosomes has been reached yet. We analyzed small extracellular vesicle (sEV)-associated DNA of eleven metastatic colorectal cancer (mCRC) patients and compared the results obtained by microarray and droplet digital PCR (ddPCR) to those reported on the ctDNA fraction. We detected the same mutations found in tissue biopsies and ctDNA in all samples but, unexpectedly, in one sample, we found a KRAS mutation that was not identified either in ctDNA or tissue biopsy. Furthermore, to assess the exact location of sEV-associated DNA (outside or inside the vesicle), we treated with DNase I sEVs isolated with three different methodologies. We found that the DNA inside the vesicles is only a small fraction of that surrounding the vesicles. Its amount seems to correlate with the total amount of circulating tumor DNA. The results obtained in our experimental setting suggest that integrating ctDNA and sEV-associated DNA in mCRC patient management could provide a complete real-time assessment of the cancer mutation status.

scholarly journals Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer

2018 ◽  
Vol 8 (1) ◽  
pp. 408-417 ◽  
Author(s):  
Hiroki Osumi ◽  
Eiji Shinozaki ◽  
Yoshinori Takeda ◽  
Takeru Wakatsuki ◽  
Takashi Ichimura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Deep Sequencing ◽  
Clinical Relevance ◽  
Circulating Tumor Dna ◽  
Tumor Dna

scholarly journals Change in circulating tumor DNA after hepatic resection for metastatic colorectal cancer

HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S25
Author(s):  
R.R. Narayan ◽  
M.L. Babicky ◽  
D.A. Goldman ◽  
M. Gonen ◽  
P.J. Allen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatic Resection ◽  
Metastatic Colorectal Cancer ◽  
Circulating Tumor Dna ◽  
Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document